BACKGROUND: Melanoma escape mechanisms include immunosuppressive and angiogenic cytokine production. OBJECTIVE: We sought to determine vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) expression by immunohistochemistry, and soluble circulating plasma levels of VEGF, bFGF, IL-10, and transforming growth factor-beta2 in patients with different stages of melanoma. METHODS: Biopsy specimens from 42 patients with primary melanoma and 9 with cutaneous metastases were studied by immunohistochemistry. In another 46 patients with melanoma (8 stage I and II; 18, III; and 20, IV) and in 10 healthy control participants, bFGF, VEGF, IL-10, and transforming growth factor-beta2 circulating levels were analyzed. RESULTS: bFGF was positive in 85% and VEGF in 47.5% of 42 primary melanomas. Of 10 patients with primary melanoma (Breslow depth 1.5-3 mm) 6 were VEGF positive and had metastases develop, whereas 4 were VEGF negative and had no metastases at 5 years of follow up. VEGF, bFGF, and IL-10 plasma levels in patients with stages III and IV melanoma were higher than the control group (P <.05 and P <.01, respectively). An inverse relationship was found between VEGF and IL-10. Specifically, in 7 patients with IL-10 levels higher than 10 pg/mL, VEGF levels were less than 49 pg/mL (P <.05); in 9 patients with VEGF levels higher than 100 pg/mL, IL-10 levels were less than 6.7 pg/mL (P <.01). CONCLUSION: VEGF expression in 1.5- to 3.0-mm Breslow depth melanomas may be considered as an unfavorable prognostic factor. Immunosuppressive (IL-10, transforming growth factor-beta2) and proangiogenic (bFGF, VEGF) cytokines are increased in metastatic melanoma. Inverse plasma levels between IL-10 and VEGF in patients with metastatic melanoma are shown in vivo for the first time, the significance of which must be further investigated.
BACKGROUND:Melanoma escape mechanisms include immunosuppressive and angiogenic cytokine production. OBJECTIVE: We sought to determine vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) expression by immunohistochemistry, and soluble circulating plasma levels of VEGF, bFGF, IL-10, and transforming growth factor-beta2 in patients with different stages of melanoma. METHODS: Biopsy specimens from 42 patients with primary melanoma and 9 with cutaneous metastases were studied by immunohistochemistry. In another 46 patients with melanoma (8 stage I and II; 18, III; and 20, IV) and in 10 healthy control participants, bFGF, VEGF, IL-10, and transforming growth factor-beta2 circulating levels were analyzed. RESULTS:bFGF was positive in 85% and VEGF in 47.5% of 42 primary melanomas. Of 10 patients with primary melanoma (Breslow depth 1.5-3 mm) 6 were VEGF positive and had metastases develop, whereas 4 were VEGF negative and had no metastases at 5 years of follow up. VEGF, bFGF, and IL-10 plasma levels in patients with stages III and IV melanoma were higher than the control group (P <.05 and P <.01, respectively). An inverse relationship was found between VEGF and IL-10. Specifically, in 7 patients with IL-10 levels higher than 10 pg/mL, VEGF levels were less than 49 pg/mL (P <.05); in 9 patients with VEGF levels higher than 100 pg/mL, IL-10 levels were less than 6.7 pg/mL (P <.01). CONCLUSION:VEGF expression in 1.5- to 3.0-mm Breslow depth melanomas may be considered as an unfavorable prognostic factor. Immunosuppressive (IL-10, transforming growth factor-beta2) and proangiogenic (bFGF, VEGF) cytokines are increased in metastatic melanoma. Inverse plasma levels between IL-10 and VEGF in patients with metastatic melanoma are shown in vivo for the first time, the significance of which must be further investigated.
Authors: Avital Gaziel-Sovran; Miguel F Segura; Raffaella Di Micco; Mary K Collins; Douglas Hanniford; Eleazar Vega-Saenz de Miera; John F Rakus; John F Dankert; Shulian Shang; Robert S Kerbel; Nina Bhardwaj; Yongzhao Shao; Farbod Darvishian; Jiri Zavadil; Adrian Erlebacher; Lara K Mahal; Iman Osman; Eva Hernando Journal: Cancer Cell Date: 2011-07-12 Impact factor: 31.743
Authors: Richard D Carvajal; Michael K Wong; John A Thompson; Michael S Gordon; Karl D Lewis; Anna C Pavlick; Jedd D Wolchok; Patrick B Rojas; Jonathan D Schwartz; Agop Y Bedikian Journal: Eur J Cancer Date: 2014-06-12 Impact factor: 9.162
Authors: Parvin Rajabi; Ali Neshat; Mozhgan Mokhtari; Mohammad A Rajabi; Mehdi Eftekhari; Payam Tavakoli Journal: J Res Med Sci Date: 2012-06 Impact factor: 1.852
Authors: Ferdinand Toberer; Holger A Haenssle; Martin Laimer; Monika Heinzel-Gutenbrunner; Alexander Enk; Wolfgang Hartschuh; Peter Helmbold; Heinz Kutzner Journal: Acta Derm Venereol Date: 2020-08-18 Impact factor: 3.875
Authors: M E Polak; N J Borthwick; F G Gabriel; P Johnson; B Higgins; J Hurren; D McCormick; M J Jager; I A Cree Journal: Br J Cancer Date: 2007-06-12 Impact factor: 7.640
Authors: Travis E Grotz; James W Jakub; Aaron S Mansfield; Rachel Goldenstein; Elizabeth Ann L Enninga; Wendy K Nevala; Alexey A Leontovich; Svetomir N Markovic Journal: Oncoimmunology Date: 2015-06-01 Impact factor: 8.110